Khanna Chand
National Institutes of Health, National Cancer Institute, Pediatric Oncology Branch, Tumor Metastasis Biology Section, 37 Convent Drive, Bethesda, MD 20892, USA.
Curr Oncol Rep. 2008 Jul;10(4):350-8. doi: 10.1007/s11912-008-0054-3.
For patients with osteosarcoma, the development of metastases, often to the lungs, is the most common cause of death. Long-term outcomes for patients who present with localized or disseminated disease have largely remained unchanged over the past 20 years. Further improvements in outcome are not likely to come from intensification of cytotoxic chemotherapy; as such, new targets for treatment are needed. A view toward such targets in osteosarcoma may be constructed based on three common clinical features of the disease. These include the origin of osteosarcoma in the bone or primitive mesenchymal cells, the predictable process of metastatic progression characterized by this disease, and the development of metastatic lesions almost exclusively in the lung. It is likely and potentially favorable for some targets to be relevant for more than one process. This review summarizes novel targets under evaluation for the treatment of osteosarcoma based on these three features of the disease.
对于骨肉瘤患者，发生转移（通常转移至肺部）是最常见的死亡原因。在过去20年里，出现局限性或播散性疾病的患者的长期预后基本没有变化。进一步改善预后不太可能通过强化细胞毒性化疗来实现；因此，需要新的治疗靶点。可以基于该疾病的三个常见临床特征来构建针对骨肉瘤此类靶点的观点。这些特征包括骨肉瘤起源于骨或原始间充质细胞、该疾病所具有的可预测的转移进展过程，以及转移病灶几乎只在肺部发生。某些靶点可能与多个过程相关，这是有可能且潜在有利的。本综述基于该疾病的这三个特征总结了正在评估的用于治疗骨肉瘤的新靶点。
